CORT Stock: Corcept Therapeutics Incorporated Stock Price, Analysis & Insights
Get live cort stock price $34.80, comprehensive Corcept Therapeutics Incorporated stock analysis, charts, news, and expert forecast. Real-time cort stock data and investment insights.
Loading chart...
Company Overview
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Company Information
- CEO
- Joseph K. Belanoff
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 500
Contact Information
- Website
- https://www.corcept.com
- Address
- 149 Commonwealth Drive
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 40.0)
✓ Lower volatility stock (Beta: 0.20) may provide portfolio stability
Business Model & Strategy
Corcept Therapeutics Incorporated operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Joseph K. Belanoff, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Corcept Therapeutics Incorporated competes in the Biotechnology within the broader Healthcare. With 3.7 billion in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, Corcept Therapeutics Incorporated provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Corcept Therapeutics Incorporated should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Corcept Therapeutics Incorporated shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Corcept Therapeutics Incorporated
- ⚠Investors should consider how Corcept Therapeutics Incorporated fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 40.0) requires strong growth to justify
Market Cap
3.66B
P/E Ratio
40.00
Beta
0.20
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 3.66B market capitalization
- Trading Volume: 20.16M shares traded today
- Price Range: 52-week range of $32.99 - $117.33
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated (CORT) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 3.66B, the company represents a significant player in its market. The stock is currently trading at $34.80 with a negativedaily change of 50.42%.
The company's 500 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 40.00, beta of 0.20, and 52-week price range from $32.99 to $117.33when evaluating investment opportunities.
Why Invest in Corcept Therapeutics Incorporated?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Joseph K. Belanoff
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.